GCP QA and Compliance Director at ERG at ERG Holding Company - New Providence, NJ, US
Woodland Intl Research group consists of 2 Phase I Units for your early phase research and generic drug development. These units are dedicated research sites that are capable of conducting inpatient and outpatient studies (including Phases I-IV studies) . These sites offer access to a diverse range of healthy volunteers and patient populations in the state of Arkansas and surrounding areas. Our Phase I Units offer the state-of-the-art facilities you need to conduct your phase I/IIa studies. Averaging 12,000 square feet and ranging from 10 to 30 beds at each location., private/semi-private male and female dormitories with showers, kitchens, study rooms, indoor/outdoor recreation areas, and group activities. We are capable of conducting Pediatric, Adolescent and Adult studies.Woodland sites provide capabilities and testing equipment to conduct all forms of early phase research from first-in- human with healthy normals to proof-of-concept with special populations. Our experienced clinical investigators, coordinators, and staff will provide controlled pharmacokinetic (PK)pharmacodynamic (PD), safety, and tolerability studies to get a new compound approved for further testing. Additional beds accommodate larger drug interaction studies, dose-ranging studies,Bioavailability and Bioequivalence studies and testing on demographically diverse disease populations to establish efficacy. Please do not hesitate to contact us for additional information or for Investigators' CV or to schedule a site visit.